GBR 830 is an Investigational, anti-OX40 Monoclonal Antibody for treatment of Atopic Dermatitis
Glenmark Pharmaceuticals announced positive data from a Phase 2a study of GBR 830, an investigational, anti-OX40 monoclonal antibody, in atopic dermatitis (AD), a common and serious chronic skin disease. The study evaluated the safety, biological and clinical activity, and pharmacokinetics of GBR 830, relative to placebo, in adults with moderate-to-severe AD with history of inadequate response to topical therapies. Based on the results of this Phase 2a study, Glenmark is firmly committed to advancing GBR 830 for patients with AD and plans to initiate a Phase 2b trial in the first half of calendar year 2018.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content